UCB Acquires Candid Therapeutics for Up to $2.2 Billion: The T‑Cell Engager Bet That Could Redefine Immunology

The Sunday Evening News That Quietly Reshaped Immunology

Last Sunday evening, while most of us were winding down the weekend, the biopharmaceutical world witnessed a seismic moment, though it didn’t arrive with the fanfare you’d expect for a deal of this magnitude. UCB, the Belgian pharma with a market cap hovering around $4 billion, sent out a press release confirming it had signed a definitive agreement to acquire Candid Therapeutics, a privately held San Diego biotech, in a transaction valued at up to $2.2 billion.

If you blinked, you might have missed it. But you shouldn’t. Because this isn’t just a line‑item in a pharma M&A database. This deal represents a deliberate, quietly confident bet that T‑cell engagers — a technology most people still associate exclusively with oncology, could become the backbone of how we treat severe autoimmune diseases. And honestly, it might just work.

Let me walk you through the whole thing. I promise I’ll make the science feel like a conversation, not a textbook, and we’ll explore why UCB’s move here feels less like a gamble and more like a masterfully timed chess play.

The Headline Deal: UCB × Candid Therapeutics at a Glance

Here are the nuts and bolts before we unpack the deeper story.

UCB announced it will pay $2 billion upfront, with an additional $200 million tied to future development and regulatory milestones — putting the total potential value at $2.2 billion. The transaction is expected to close by the end of the second quarter or early third quarter of 2026, pending antitrust clearance and other customary closing conditions.

Candid Therapeutics, founded in 2024 and based in sunny San Diego, is a clinical‑stage company redefining the treatment of autoimmune and inflammatory diseases through novel T‑cell engagers — a class of immunotherapies originally pioneered in blood cancers that are now being redirected at rheumatology, nephrology, and neurology indications. Think of T‑cell engagers as the technology that learned to hunt cancer cells, and is now being retrained to identify and eliminate the immune cells that mistakenly attack our own bodies.

The lead asset is cizutamig (more on that in a bit, it’s the real star of this story), a bispecific antibody targeting BCMA on plasma cells and CD3 on T‑cells, already tested in over 100 patients across oncology and autoimmune settings. That’s not just preclinical promise, that’s actual human data, and a lot of it.

Why This Isn’t Just Another Biotech Acquisition

Here’s where I pause and tell you something you might find surprising.

Most big pharma acquisitions are about buying certainty, proven Phase 3 assets, near‑term revenue, de‑risked pipelines. But this? This is different. UCB is going all in on a technology platform that’s still early in its autoimmune journey. Cizutamig is in Phase 1/2 clinical studies across more than 10 autoimmune indications, not Phase 3, not NDA‑ready.

So why do it? Because UCB sees something the rest of the industry is only beginning to grasp: T‑cell engagers don’t just treat autoimmune diseases, they have the potential to reset the immune system.

Think of it this way. Most current autoimmune treatments, including UCB’s own blockbuster‑in‑the‑making bimekizumab (Bimzelx), work by continuously suppressing inflammatory pathways. You take them, you feel better, but if you stop, the disease typically roars back. They’re like a dam holding back a river. What UCB is betting on here is something fundamentally different: removing the pathogenic immune cells so the body can rebuild from scratch, a true immune reset.

That shift in philosophy, from chronic suppression to potential disease modification, is what makes this acquisition so compelling.

T‑Cell Engagers 101: The “Smart Bridge” Inside Your Immune System

Okay, let’s step back for a moment. I know we’ve thrown around “T‑cell engager” a few times now, and if you’re not a PhD in immunology, that phrase probably feels like jargon. But I promise you, the concept is surprisingly simple and genuinely elegant.

Imagine your immune system is a security team patrolling a building. The T‑cells are the special forces soldiers, highly trained, lethal, but extremely picky about what they attack. They won’t mobilize unless they’re absolutely certain a target is hostile. Most of the time, that’s a good thing, it prevents friendly fire. But in autoimmune diseases, the real threat often goes unnoticed because the offending B‑cells or plasma cells don’t present the right “danger signals” for T‑cells to recognize on their own.

A bispecific T‑cell engager is like a smart bridge. One arm of the antibody grabs onto a specific protein on the pathogenic cell, say, BCMA on a plasma cell. The other arm grabs onto CD3, a protein on the surface of a T‑cell. By physically linking them together, the engager brings the killer and the target so close that the T‑cell activates and destroys the pathogenic cell, without needing any additional confirmation signals.

It’s the biological equivalent of a police officer pointing at a suspect and saying, “Him. Right there. Go.” The T‑cell doesn’t hesitate, it just acts.

First‑generation TCEs proved this works brilliantly in blood cancers like multiple myeloma, where blinatumomab (Blincyto) and teclistamab have produced deep remissions in patients who had run out of options. Now, the question is: can the same approach work against the rogue immune cells driving lupus, rheumatoid arthritis, myasthenia gravis, and dozens of other devastating autoimmune conditions?

Early data from Candid, and others, suggests the answer is yes.

Cizutamig: The Crown Jewel of Candid’s Pipeline

If this acquisition is a bet on T‑cell engagers in autoimmunity, cizutamig is the poker chip sitting at the center of the table. Let’s talk about why this particular molecule has UCB so excited.

Cizutamig is a bispecific antibody targeting B‑cell maturation antigen (BCMA) on plasma cells and CD3 on T‑cells. In plain English? It zeroes in on plasma cells, the antibody‑producing factories that, in autoimmune diseases, churn out the misguided antibodies attacking the body’s own tissues. Once the T‑cell is bound to the plasma cell via cizutamig, the T‑cell unleashes its cytotoxic machinery and eliminates it.

Here’s what makes cizutamig stand out from the crowd:

1. Deep clinical experience already in hand. Over 100 patients have been treated with cizutamig, including roughly 80 patients across autoimmune diseases and dozens more in oncology settings. That’s not a theoretical asset, it’s a molecule with real‑world human data.

2. On‑target pharmacology with deep B‑cell and plasma cell depletion in tissues. In autoimmune patients, cizutamig doesn’t just clear cells from the blood, it penetrates tissues where pathogenic plasma cells hide out, achieving deep depletion that other therapies struggle to reach.

3. Encouraging safety with a differentiated profile. Cytokine release syndrome (CRS) is the bugbear of T‑cell engagers, it’s what happens when T‑cells get a little too excited during activation. With cizutamig, mild CRS occurred in fewer than 20% of patients, and there have been no cases of immune effector cell‑associated neurotoxicity syndrome (ICANS) — a serious neurological complication seen with some CAR‑T therapies. This favorable tolerability has also enabled outpatient dosing, a huge practical advantage over infused cell therapies.

4. Efficacy in patients who’ve failed everything else. Cizutamig has shown promising clinical responses in patients who previously failed rituximab (anti‑CD20), efgartigimod (anti‑FcRn), complement inhibitors, and other standard‑of‑care drugs. In other words, when existing options run dry, cizutamig still delivers.

UCB clearly sees cizutamig as a potential best‑in‑class BCMA TCE for autoimmune diseases. And looking at the data, that confidence doesn’t feel misplaced.

Beyond Cizutamig: Candid’s Ground‑Breaking Multi‑Specific Platform

One asset is great. A whole platform is better. And that’s really what UCB is buying here,  a modular, multi‑target approach to T‑cell engagers that can address autoimmune diseases from multiple angles simultaneously.

In addition to cizutamig (BCMA/CD3), Candid has been developing:

• CND261, a CD20‑targeting TCE that has been dosed in more than 110 patients (including over 20 with autoimmune diseases), also showing deep B‑cell depletion and an even milder safety profile, only Grade 1 CRS in fewer than 20% of patients, with no ICANS.
• CND319, a dual‑targeting CD19 and CD20 TCE designed to achieve broader B‑cell depletion than single‑antigen approaches. This program is moving into first‑in‑human trials in 2026.

This multi‑pronged approach matters because autoimmune diseases are complex beasts. No single B‑cell population drives every disease, and patients can develop resistance when one pathway is blocked. By having multiple TCEs targeting different antigens, BCMA, CD20, CD19/CD20, and more, UCB can tailor its approach to specific diseases and patient populations while hedging against the risk that any single asset stumbles in development.

It’s the difference between owning a single lottery ticket and owning a diversified portfolio of carefully selected bets.

How This Builds Upon UCB’s Existing Immunology Powerhouse

Here’s where the strategic picture really comes together. UCB isn’t a newcomer to immunology, far from it.

The company’s existing pipeline already includes bimekizumab (Bimzelx), a dual IL‑17A and IL‑17F inhibitor approved for psoriasis and psoriatic arthritis that has been generating strong revenue momentum. It also includes rozanolixizumab, an FcRn inhibitor that targets pathogenic IgG autoantibodies, currently being studied in myasthenia gravis and other neurological autoimmune conditions.

But here’s the thing about those therapies: they work upstream, soaking up inflammatory signals or preserving the antibodies that are already causing damage. T‑cell engagers, by contrast, work at the source — they eliminate the B‑cells and plasma cells producing the pathogenic antibodies in the first place.

When combined, these platforms could create a comprehensive suite of immunology solutions that spans the entire disease mechanism:

• Bimekizumab → neutralizes inflammatory cytokines (symptom control)
• Rozanolixizumab → removes existing pathogenic antibodies (damage control)
• Cizutamig and Candid’s TCEs → depletes the cells that make those antibodies (root cause removal)

And let’s not forget: UCB had already signaled its commitment to T‑cell engagers earlier in 2026 with its $1.18 billion licensing deal with Antengene for ATG‑201, a CD19/CD3 bispecific TCE with a novel masking technology designed to reduce CRS risk. Together, these complementary investments expand UCB’s reach across multiple B‑cell targets and disease mechanisms, strengthening its ability to address antibody‑mediated autoimmune diseases through differentiated, biology‑driven approaches.

The CEO, Jean‑Christophe Tellier, put it plainly: “This acquisition demonstrates our inorganic innovation strategy in action and marks a pivotal moment for UCB, as we secure a significant technological advancement in the field with the addition of cizutamig to our pipeline”.

That’s not marketing spin. It’s the articulation of a deliberate, well‑orchestrated pivot.

The “Immune Reset” Vision: Why It’s a Genuine Paradigm Shift

I mentioned “immune reset” earlier, and I want to linger on this for a moment because it’s genuinely the most exciting, and most misunderstood, concept in this entire story.

Most people living with autoimmune diseases are stuck on a treadmill of chronic treatment. They take a biologic injection every two weeks, or an immunosuppressant pill every morning, and their disease quiets down, but if they miss a dose, symptoms creep back. Over time, some drugs lose effectiveness. Side effects accumulate. The disease is managed, not cured.

Immune reset proposes something radically different: What if you could eliminate the pathogenic immune cells, let the body rebuild a fresh, healthy immune repertoire, and achieve long‑term, treatment‑free remission?

Early evidence suggests T‑cell engagers, particularly those targeting BCMA, CD19, and CD20, might be able to do exactly that. By deeply depleting the offending B‑cell and plasma cell populations, they create a “blank slate” from which the immune system can regenerate. The new cells that repopulate tend to be naïve (non‑self‑reactive), breaking the cycle of autoantibody production.

It’s not a guaranteed cure. It’s not even guaranteed to work for every patient or every disease. But it represents a philosophical leap from “manage this forever” to “reset, restore, and possibly move on.”

For the millions of people living with severe lupus, Sjögren’s syndrome, systemic sclerosis, ANCA‑associated vasculitis, myasthenia gravis, and other devastating antibody‑mediated conditions, that’s not just progress. That’s hope.

Market Implications and the Competitive Landscape

A quick reality check: UCB isn’t operating in a vacuum.

The race to deploy T‑cell engagers in autoimmunity is heating up rapidly. Gilead Sciences made its own massive bet just weeks earlier, announcing the acquisition of Ouro Medicines for $2 billion, centered on a clinical‑stage BCMA CD3 T‑cell engager called OM336. Other players, large and small, are circling the same opportunity.

The global T‑cell engager market, valued at approximately $2.4 billion in 2024, is projected to grow at a compound annual growth rate exceeding 20%, potentially reaching $19 billion by 2034 as these therapies expand from oncology into immunology. That’s a massive addressable market, and UCB’s combined platform positions it as a formidable early mover.

What sets UCB apart? Two things:

1. An existing immunology commercial infrastructure. UCB already has relationships with rheumatologists, neurologists, and payers through bimekizumab, rozanolixizumab, and Cimzia (certolizumab pegol). When a TCE does eventually get approved, UCB won’t be starting from zero, it’ll be expanding a mature franchise.

2. A multi‑target, platform‑driven strategy rather than a single‑asset gamble. By acquiring Candid’s entire pipeline, plus the Antengene deal, UCB is covering multiple B‑cell targets (BCMA, CD19, CD20) and multiple disease mechanisms. If one program fails, the thesis isn’t dead.

With a combined pro‑forma cash position of around $700 million following Candid’s merger with Rallybio and subsequent financing, the merged entity has the financial runway to advance through multiple Phase 2 readouts without immediate dilution risk.

A Platform Bet, Not a Product Bet

Here’s the thing I’d leave you with: it’s easy to look at this deal and reduce it to a transaction, $2.2 billion for a clinical‑stage asset in autoimmune disease. But that framing misses the point entirely.

What UCB is doing is building a technology platform for the next decade of immunology. It’s not just buying cizutamig; it’s buying a modular architecture for T‑cell engagers that can be iterated, optimized, and deployed across dozens of diseases. When you add that to UCB’s existing monoclonal antibody and FcRn inhibitor franchises, you start to see a company that’s architecting a comprehensive, layered strategy for immune‑mediated disease, from symptom suppression to antibody removal to deep cellular depletion and, ultimately, immune reset.

The transaction isn’t just about what Candid is today. It’s about what UCB can become over the next 5 to 10 years. And frankly, it’s hard not to be impressed.

If cizutamig lives up to its clinical promise, and there’s good reason to believe it will, we might look back on this Sunday evening announcement as the moment the immunology field took an irreversible turn toward cell‑targeted, restorative medicine. And UCB will have been there first.